EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER

Yuxuan Gao, Shiyao Jiang, Yu Cui, Yumeng Wang, Lili Yu iD

PLOS One · 09.01.2026 · 21 (1) · e0340794

DOI: 10.1371/journal.pone.0340794 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS One, online erschienen am 09.01.2026. Verfasst von Yuxuan Gao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Shandong Second Medical University, Weifang, Shandong, China. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, B7-H1 Antigen, Immune Checkpoint Inhibitors, Endocrine System Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weifang Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the extensive clinical application of immune checkpoint inhibitors (ICIs), immune-related adverse events (irAEs) associated with these agents have increasingly garnered significant attention. Unlike other irAEs, endocrine irAEs are mostly irreversible, with variable and nonspecific symptoms, which poses challenges for clinicians in diagnosis. As a result, this study leveraged the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) pharmacovigilance databases to conduct an in-depth investigation into adverse events induced by PD-1/PD-L1 inhibitors, with a focus on irAEs induced by PD-1/PD-L1 inhibitors. This study pioneers the systematic cross-database validation of endocrine irAEs induced by PD-1/PD-L1 inhibitors. The integration of data from the JADER offers unique safety insights for Asian populations, bolsters global pharmacovigilance efforts, and uncovers regional variations in irAEs reporting. Notably, this study revealed a higher prevalence of endocrine irAEs among men aged over 50 years receiving PD-1/PD-L1 inhibitors. Both PD-1 and PD-L1 inhibitors are strongly associated with thyroid dysfunction, adrenal insufficiency, and pituitary inflammation. Additionally, it identifies several previously undocumented endocrine irAEs. This result unearthed safety signals hitherto unreported in drug inserts, underscoring the imperative for updating the safety labeling of PD-1/PD-L1 inhibitors with respect to endocrine irAEs. The emergence of off-label uses further underscores the need for additional clinical trials to assess their efficacy and safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint InhibitorsEndocrine System DiseasesHumansAdverse Drug Reaction Reporting SystemsUnited StatesPharmacovigilanceJapanDatabases, FactualUnited States Food and Drug Administration

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Public Health, Shandong Second Medical University, Weifang, Shandong, China.
  • Department of Medicine Information, The 960th Hospital of the PLA Joint Logistics Support Force, Jinan, Shandong, China.

ORCID-Profile: Lili Yu

Förderung

  • Weifang Medical University

Zitieren

APA

Gao, Y., Jiang, S., Cui, Y., Wang, Y., & Yu, L. (2026). Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER. PLOS One, 21(1), e0340794. https://doi.org/10.1371/journal.pone.0340794

Vancouver

Gao Y, Jiang S, Cui Y, Wang Y, Yu L. Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER. PLOS One. 2026;21(1):e0340794. doi:10.1371/journal.pone.0340794

BibTeX
@article{Gao2026,
  author = {Gao, Yuxuan and Jiang, Shiyao and Cui, Yu and Wang, Yumeng and Yu, Lili},
  title = {Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {1},
  pages = {e0340794},
  doi = {10.1371/journal.pone.0340794}
}
Kostenlos starten →